All episodes

In this weeks episode of Diabetes Insights - Breakthroughs and Innovators, experts discuss the highly anticipated SURPASS CVOT trial, a head-to-head cardiovascular outcomes study comparing tirzepatide 15 mg weekly with dulaglutide 1.5 mg weekly in people with type 2 diabetes. With over 13,000 participants, the trial demonstrates that tirzepatide provides equivalent cardioprotective benefits to dulaglutide, confirming its role in improving both glycaemic control and cardiovascular outcomes.

EASD TV Host Vivienne Parry sits with Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD Independent Advisor and McMaster University) to unpack the trial’s implications for clinical practice, highlighting how outcomes...

In our first episode of 2026, Prof. Hindrik Mulder, Editor-in-Chief of Diabetologia, offers a journal’s-eye view of the most exciting and challenging developments in diabetes research today.

Drawing on his unique overview of submissions from across the global research community, prof. Mulder discusses emerging breakthroughs such as hypoimmune stem cell-based therapies that are transforming from theoretical possibilities into scalable, off-the-shelf treatments for diabetes. Prof. Mulder discusses how these innovations could revolutionise diabetes care by overcoming the historical barriers of islet transplantation.

We further explore Diabetologia's special 2025 issue on "Opportunities and Challenges in Diabetes," which tackles the critical issues of...

In this episode, Dr. Tamara Hannon (Indiana University Health) and Prof. Martin Wabitsch (Universtätsklinikum Ulm) unpack the findings of the SURPASS-PEDS trial - the first study to evaluate the dual GIP/GLP-1 receptor agonist tirzepatide in adolescents with type 2 diabetes.

With youth-onset type 2 diabetes rising sharply across the US and Europe, and with young people experiencing faster beta-cell decline, more severe obesity, and greater socioeconomic burdens, the need for effective therapies has never been greater. They discuss why adolescent disease differs fundamentally from adult type 2 diabetes, why weight-loss expectations cannot be compared across age groups, and how tirzepatide...

In this episode, EASD presents its inaugural clinical guideline on diabetes distress. Drawing on two years of multidisciplinary work, the guideline was developed by clinicians, methodologists, psychologists and people with lived experience. Prof. Jane Speight, Prof. Richard Holt and patient-advocate Michelle Law describe what diabetes distress is (the emotional burden tied to daily self-management) and why routine assessment and supportive care must become part of standard practice.

The guideline sets out eight good practice statements to help clinicians normalise conversations about emotional wellbeing, plus graded recommendations for managing distress in adults with type 1 and type 2 diabetes. Psychological interventions...

In this episode, leading experts Anette Ziegler (Helmholtz Munich), Chantal Mathieu (KU Leuven & EASD President), and Anastasia Albanese-O’Neill (Breakthrough T1D) join EASD TV to discuss the emerging global consensus on screening for early-stage type 1 diabetes.

They explore why population-wide screening is now considered both feasible and essential, how early detection can prevent DKA and enable access to disease-modifying therapies, and what the new guidance means for clinicians, health systems, and policymakers.

From optimal screening ages and two-step testing strategies to implementation challenges, cost-effectiveness, and the promise of prevention, this conversation outlines one of the most significant shifts in...

Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 diabetes.

The trial followed more than 8,000 high-risk participants and demonstrated a 14% reduction in major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. Dr Cavender explains why having an effective oral GLP-1 receptor agonist is an important development for both diabetes...

At the EASD 2024 Annual Meeting, the SOUL trial attracted significant attention as the first study to show cardiovascular risk reduction using an oral GLP-1 receptor agonist. In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains the trial’s major outcomes, including a 14% reduction in major adverse cardiovascular events -matching results previously observed with injectable GLP-1 formulations.

The discussion highlights the potential impact of an oral agent on clinical practice, including improved accessibility, suitability for older adults, and earlier use in the treatment pathway. Dr Busui also reviews new data on heart failure phenotypes, particularly...

In this episode, Dr. Sean Wharton (University of Toronto and Wharton Medical Clinic, Canada) and Dr. Nasreen Alfaris (King Fahad Medical City, Riyadh, Saudi Arabia) join host Vivienne Parry to discuss the groundbreaking ATTAIN trial, presented at the EASD 2025 Annual Meeting in Vienna.

The trial tested Orforglipron, the first oral small molecule GLP-1 receptor agonist, showing promising results in weight reduction and cardiometabolic improvements among people living with overweight or obesity.

Beyond the data, the discussion explores what makes Orforglipron different, from its potential to expand access and affordability, to its implications for type 2 diabetes prevention. With obesity...

What does the future hold for beta cell biology and diabetes treatment? Join Prof. Raphaël Scharfmann (INSERM), recipient of the 2025 Albert Renold Prize, as he explores how developmental biology is unlocking new ways to generate functional beta cells - an important step toward curing diabetes.
In this inspiring interview from the EASD 2025 Annual Meeting in Vienna, Prof. Scharfmann discusses the progress in stem cell-derived beta cell generation, the collaboration driving translational research, and the next big challenge, counting beta cells in the living human pancreas.
Discover how decades of research are shaping the next frontier in diabetes science...

In this episode, Vivienne Parry introduces the EASD Rising Stars of 2025, four early-career researchers whose work spans exercise physiology, precision diabetes medicine, childhood obesity, and metabolic biology.

Dr Sindre Lee-Ødegård (Norway) explores exercise as medicine for highrisk groups; Dr Martin Schön (Slovakia/Germany) works on precision diabetes diagnosis and lifestyle interventions; Dr Cadenas-Sánchez (Spain) investigates childhood obesity and brain health; and Dr Jens Lund (Denmark) uncovers how metabolites like lactate act as powerful signalling molecules.

From exercise as medicine to precision diabetes care, childhood obesity, and molecular metabolism, these young scientists are redefining how we understand, prevent, and treat diabetes.Together,...